KIT EXPRESSION

CI-VAR-00000937Explore in graph →CIViC 429

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor2
KIT EXPRESSION	Imatinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID2480 In a prospective phase III study (SWOG S0033/CALGB 150105) of 407 patients with gastrointestinal stromal tumors (GISTs), 397 patients were observed to be CD117-positive (i.e. KIT-positive) and 10 pati… (full text at CIViC) PMID 18955451 · Heinrich et al., 2008 · Open in CIViC	civic
KIT EXPRESSION	Imatinib	Predictive	B	Supports Resistance	—	submitted	EID2488 Primary KIT mutations are detected in 75-80% of GIST patients, and primarily occur in exons 9 and 11, wheareas secondary KIT mutations associated with resistance to imatinib are found in exons 13,14, … (full text at CIViC) PMID 16551858 · Wardelmann et al., 2006 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Glioblastoma1
KIT EXPRESSION	Sunitinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID10180 Phase II trial of sunitinib in 40 patients with first recurrence of primary glioblastoma. Median PFS 2.2 mo, median OS 9.2 mo, 5 stable disease >=6 months, no objective responses, so primary study end… (full text at CIViC) PMID 24311637 · Hutterer et al., 2014 · Open in CIViC	civic

Malignant Endometrial Neoplasm2
KIT EXPRESSION	Imatinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID1024 Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT). PMID 18607592 · Kalender et al., 2009 · Open in CIViC	civic
KIT EXPRESSION	Imatinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID1025 Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment… (full text at CIViC) PMID 16487996 · Salvatierra et al., 2006 · Open in CIViC	civic

Ocular Melanoma1
KIT EXPRESSION	Dasatinib	Predictive	C	Does Not Support Sensitivity Response	1	submitted	EID7758 In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients receiving dasatinib without prior biomarker screening, six patients achieved clinical benefit (2 PR; 4 SD)… (full text at CIViC) PMID 21523734 · Kluger et al., 2011 · Open in CIViC	civic